Skip to content

Study · Non-randomized trial · n = 5 · 1977

4 results

Vasoactive intestinal peptide: a secretin-like partial agonist for pancreatic secretion in man.

Domschke S, Domschke W, Rösch W, Konturek SJ, Sprügel W, Mitznegg P, Wünsch E, Demling L

Gastroenterology1 Sept 1977Cited by 30 (Europe PMC)

PMID892345 (opens in a new tab)DOI10.1016/s0016-5085(19)32126-2 (opens in a new tab)PepBankPUB-00892345
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, the maximal VIP-evoked pancreatic juice flow was lower than the maximal secretin-stimulated flow.

    In plain wordsIn healthy volunteers, VIP caused much less pancreatic juice flow than secretin.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseMaximal pancreatic juice flow
    Study

    n = 5

    Comparator
    Secretin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.8 to 3.2 microgram per kg per hr · intravenousAs given in this study (human).

    Measurements

    Maximal juice flow
    48 microliter per kg per 5 min
    VIP
    Maximal juice flow
    248 microliter per kg per 5 min
    secretin

    Source sentences

    Summary
    The mean +/- SEM observed maximal response of secretin-stimulated juice flow was 248 +/- 7 microliter per kg per 5 min, whereas the observed maximal response for VIP-evoked juice flow was 48 +/- 6 microliter per kg per 5 min.
    1 context sentence
    Summary · context
    The responses of pancreatic volume flow and bicarbonate output to intravenous vasoactive intestinal peptide (VIP, 0.8 to 3.2 microgram per kg per hr) and synthetic secretin (32.2 to 129 ng per kg per hr) were compared intraindividually in 5 healthy volunteers.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, the maximal VIP-related bicarbonate output was lower than the maximal secretin-induced output.

    In plain wordsIn healthy volunteers, VIP caused much less pancreatic bicarbonate output than secretin.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseMaximal pancreatic bicarbonate output
    Study

    n = 5

    Comparator
    Secretin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.8 to 3.2 microgram per kg per hr · intravenousAs given in this study (human).

    Measurements

    Maximal bicarbonate output
    4.3 muEq per kg per 5 min
    VIP
    Maximal bicarbonate output
    30 muEq per kg per 5 min
    secretin

    Source sentences

    Summary
    The observed maximal secretin-induced bicarbonate output was 30 +/- 2 muEq per kg per 5 min, and the maximal VIP-related response was 4.3 +/- 0.9 muEq per kg per 5 min.
    1 context sentence
    Summary · context
    The responses of pancreatic volume flow and bicarbonate output to intravenous vasoactive intestinal peptide (VIP, 0.8 to 3.2 microgram per kg per hr) and synthetic secretin (32.2 to 129 ng per kg per hr) were compared intraindividually in 5 healthy volunteers.
  3. 03HumanNon-randomized trialSafety outcome

    In healthy volunteers, VIP at 3.2 micrograms per kg per hr caused a significant rise in pulse rate.

    In plain wordsIn healthy volunteers, the highest VIP dose raised the pulse rate.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePulse rate rise
    Study

    n = 5

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    3.2 micrograms per kg per hr · intravenousAs given in this study (human).

    Source sentences

    Summary
    side effects (significant rise in pulse rate and cutaneous flushing at 3.2 micrograms per kg per hr)
    1 context sentence
    Summary · context
    The responses of pancreatic volume flow and bicarbonate output to intravenous vasoactive intestinal peptide (VIP, 0.8 to 3.2 microgram per kg per hr) and synthetic secretin (32.2 to 129 ng per kg per hr) were compared intraindividually in 5 healthy volunteers.
  4. 04HumanNon-randomized trialSafety outcome

    In healthy volunteers, VIP at 3.2 micrograms per kg per hr caused cutaneous flushing.

    In plain wordsIn healthy volunteers, the highest VIP dose caused skin flushing.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseCutaneous flushing
    Study

    n = 5

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    3.2 micrograms per kg per hr · intravenousAs given in this study (human).

    Source sentences

    Summary
    side effects (significant rise in pulse rate and cutaneous flushing at 3.2 micrograms per kg per hr)
    1 context sentence
    Summary · context
    The responses of pancreatic volume flow and bicarbonate output to intravenous vasoactive intestinal peptide (VIP, 0.8 to 3.2 microgram per kg per hr) and synthetic secretin (32.2 to 129 ng per kg per hr) were compared intraindividually in 5 healthy volunteers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.